IR-Med (IRME) Stock Price

IR-Med Price

NYSE·CLOSED
0.00
​
Market closed

IR-Med stock price

Access this data via the Eulerpool API

IR-Med business model & stock analysis

IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2001-07-18. The firm develops non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company’s devices allow healthcare professionals to detect and measure different molecules in the blood and in human tissue in real-time without any invasive procedures. Its initial product candidates are in various stages of development. The company is focused on two principal medical devices: PressureSafe and Nobiotics. PressureSafe is a handheld optical monitoring device that is being developed to support the early detection of pressure injuries (PI) to the skin and underlying tissue, primarily caused by prolonged pressure associated with bed confinement. Nobiotics is an otoscope, which is designed to support physicians with an immediate indication as to whether mid-ear infection (Otitis Media) is of a bacterial origin.

Frequently asked questions about IR-Med

Converted at the current exchange rate, the IR-Med share trades at 0.00 EUR (0.00 USD).

The expected revenue of IR-Med is 31.52 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of IR-Med is 18.71 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IR-Med is currently 0.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IR-Med stock.

The price-to-sales ratio (P/S) of IR-Med is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IR-Med stock.

The Eulerpool Quality Score for IR-Med is 2/10.

The ISIN of IR-Med is US46265R1032. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of IR-Med is IRME. The ticker symbol is used to trade IR-Med shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Jul 18, 2001
ISIN
US46265R1032
Cusip
46265R103
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
-0.13
P/Ee 2026
0.01
P/S
P/Se
0.03
EV/EBIT
—
P/B Ratio
0.62
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1,386.13 %
Last updated Oct 12, 2026, 9:00 AM

IR-Med Peer Group

IR-Med FIGI

IRME:US · BBG000BRKXG5IRME:PQ · BBG000BRL2W4IRME:UV · BBG000BRL3Q9

All fundamentals and in-depth analysis of IR-Med

Our stock analysis for IR-Med stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IR-Med. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.